T细胞疗法-话题@MedSci

#T细胞疗法#

95篇内容 | 3170人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1478036, encodeId=011214e8036e3, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=欧洲药品管理局开始审查Kite的自体CAR-T细胞疗法KTE-X19，用于治疗套细胞淋巴瘤, objectType=article, longId=187285, objectId=d73e18e28514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d73e18e28514, replyNumber=0, likeNumber=97, createdTime=2020-02-04, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d73e18e28514, moduleTitle=欧洲药品管理局开始审查Kite的自体CAR-T细胞疗法KTE-X19，用于治疗套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d73e18e28514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478035, encodeId=06a914e803599, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据, objectType=article, longId=187159, objectId=649918e159e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=649918e159e2, replyNumber=0, likeNumber=65, createdTime=2020-02-03, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=649918e159e2, moduleTitle=Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=649918e159e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478034, encodeId=daf814e8034f0, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Cellectis的同种异体CAR-T细胞疗法（UCART）开始用于治疗复发/难治性急性髓细胞白血病患者, objectType=article, longId=186372, objectId=76531863e2f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76531863e2f1, replyNumber=0, likeNumber=31, createdTime=2020-01-18, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76531863e2f1, moduleTitle=Cellectis的同种异体CAR-T细胞疗法（UCART）开始用于治疗复发/难治性急性髓细胞白血病患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76531863e2f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478033, encodeId=188114e803323, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Blood： CD19特异性CAR T细胞疗法治疗R/R B-ALL, objectType=article, longId=185565, objectId=07da185565a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07da185565a3, replyNumber=0, likeNumber=85, createdTime=2020-01-03, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07da185565a3, moduleTitle=Blood： CD19特异性CAR T细胞疗法治疗R/R B-ALL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07da185565a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478032, encodeId=337714e8032f7, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=百时美施贵宝宣布向FDA申请其CAR-T细胞疗法liso-cel的许可, objectType=article, longId=184956, objectId=2ccf1849567a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ccf1849567a, replyNumber=0, likeNumber=69, createdTime=2019-12-21, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ccf1849567a, moduleTitle=百时美施贵宝宣布向FDA申请其CAR-T细胞疗法liso-cel的许可, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ccf1849567a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478031, encodeId=599e14e803183, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿, objectType=article, longId=184904, objectId=574418490463, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=574418490463, replyNumber=0, likeNumber=60, createdTime=2019-12-19, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=574418490463, moduleTitle=百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=574418490463)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478030, encodeId=e3f714e8030f3, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=CAR-T细胞疗法在美国血液学会ASH上大放异彩, objectType=article, longId=184849, objectId=fa79184849b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa79184849b1, replyNumber=0, likeNumber=66, createdTime=2019-12-18, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa79184849b1, moduleTitle=CAR-T细胞疗法在美国血液学会ASH上大放异彩, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa79184849b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478029, encodeId=cf9614e80299f, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Kite向FDA提交第二种CAR-T细胞疗法的申请，以治疗套细胞淋巴瘤, objectType=article, longId=184844, objectId=f4f518484488, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4f518484488, replyNumber=0, likeNumber=75, createdTime=2019-12-18, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4f518484488, moduleTitle=Kite向FDA提交第二种CAR-T细胞疗法的申请，以治疗套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4f518484488)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478028, encodeId=e41d14e802806, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果, objectType=article, longId=184397, objectId=4dad18439e2a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dad18439e2a, replyNumber=0, likeNumber=35, createdTime=2019-12-09, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dad18439e2a, moduleTitle=百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dad18439e2a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478027, encodeId=daa314e802725, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Autolus的快速解离型CAR-T细胞疗法治疗急性淋巴细胞白血病，获FDA孤儿药物指定, objectType=article, longId=182512, objectId=6d2018251202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d2018251202, replyNumber=0, likeNumber=67, createdTime=2019-11-08, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d2018251202, moduleTitle=Autolus的快速解离型CAR-T细胞疗法治疗急性淋巴细胞白血病，获FDA孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d2018251202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478026, encodeId=391114e8026ce, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=科济生物CAR-T细胞疗法治疗复发或难治性多发性骨髓瘤，被FDA授予再生医学先进疗法称号, objectType=article, longId=182335, objectId=990d182335ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=990d182335ef, replyNumber=0, likeNumber=74, createdTime=2019-11-05, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=990d182335ef, moduleTitle=科济生物CAR-T细胞疗法治疗复发或难治性多发性骨髓瘤，被FDA授予再生医学先进疗法称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=990d182335ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478025, encodeId=539b14e8025cc, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Blood：Epo刺激T细胞可增强过继性T细胞疗法的抗肿瘤活性, objectType=article, longId=182245, objectId=ac0518224573, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac0518224573, replyNumber=0, likeNumber=68, createdTime=2019-11-03, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac0518224573, moduleTitle=Blood：Epo刺激T细胞可增强过继性T细胞疗法的抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac0518224573)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478024, encodeId=3f3814e8024fb, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Blood：CD19特异性CAR T细胞疗法治疗R/R B-ALL, objectType=article, longId=181713, objectId=584d181e139f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=584d181e139f, replyNumber=0, likeNumber=82, createdTime=2019-10-23, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=584d181e139f, moduleTitle=Blood：CD19特异性CAR T细胞疗法治疗R/R B-ALL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=584d181e139f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478023, encodeId=e92814e802355, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Blood：γ分泌酶抑制剂可增强BCMA靶向CAR T细胞疗法的功效, objectType=article, longId=180386, objectId=5179180386b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5179180386b8, replyNumber=0, likeNumber=71, createdTime=2019-10-03, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5179180386b8, moduleTitle=Blood：γ分泌酶抑制剂可增强BCMA靶向CAR T细胞疗法的功效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5179180386b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478022, encodeId=5c3714e802262, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Sci tranal med：BAFF-R靶向CAR T细胞疗法可克服B细胞恶性肿瘤的CD19抗原缺失, objectType=article, longId=180381, objectId=e0141803814a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0141803814a, replyNumber=0, likeNumber=67, createdTime=2019-10-03, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0141803814a, moduleTitle=Sci tranal med：BAFF-R靶向CAR T细胞疗法可克服B细胞恶性肿瘤的CD19抗原缺失, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0141803814a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478021, encodeId=c26014e802143, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Precision宣布FDA批准其靶向CD20的同种异体CAR-T细胞疗法PBCAR20A的研究新药申请IND, objectType=article, longId=179626, objectId=eba11e962686, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eba11e962686, replyNumber=0, likeNumber=39, createdTime=2019-09-19, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eba11e962686, moduleTitle=Precision宣布FDA批准其靶向CD20的同种异体CAR-T细胞疗法PBCAR20A的研究新药申请IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eba11e962686)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478020, encodeId=671814e802050, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=CARsgen Therapeutics公司的多发性骨髓瘤CAR-T细胞疗法喜获FDA的孤儿药物指定, objectType=article, longId=178782, objectId=c6a71e8782a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6a71e8782a5, replyNumber=0, likeNumber=45, createdTime=2019-09-05, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6a71e8782a5, moduleTitle=CARsgen Therapeutics公司的多发性骨髓瘤CAR-T细胞疗法喜获FDA的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6a71e8782a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478019, encodeId=270e14e8019f5, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=2019 AACR：MultiTAA T细胞疗法治疗胰腺癌, objectType=article, longId=175928, objectId=1b861e592863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b861e592863, replyNumber=0, likeNumber=66, createdTime=2019-07-24, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b861e592863, moduleTitle=2019 AACR：MultiTAA T细胞疗法治疗胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b861e592863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478018, encodeId=68b214e8018da, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=完全个体化肿瘤免疫疗法：一种针对个体化抗原的自体基因编辑的TCR T细胞疗法（NeoTCR-P1）, objectType=article, longId=175924, objectId=f0c91e5924d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0c91e5924d3, replyNumber=0, likeNumber=72, createdTime=2019-07-23, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0c91e5924d3, moduleTitle=完全个体化肿瘤免疫疗法：一种针对个体化抗原的自体基因编辑的TCR T细胞疗法（NeoTCR-P1）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0c91e5924d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478017, encodeId=733f14e8017d9, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=huMNC2-CAR44 T细胞疗法治疗转移性乳腺癌, objectType=article, longId=172184, objectId=bd6d1e2184cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd6d1e2184cc, replyNumber=0, likeNumber=73, createdTime=2019-06-27, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd6d1e2184cc, moduleTitle=huMNC2-CAR44 T细胞疗法治疗转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd6d1e2184cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

T细胞疗法

2020-05-29

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

欧洲药品管理局开始审查Kite的自体CAR-T细胞疗法KTE-X19，用于治疗套细胞淋巴瘤

2020-02-04

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据

2020-02-03

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Cellectis的同种异体CAR-T细胞疗法（UCART）开始用于治疗复发/难治性急性髓细胞白血病患者

2020-01-18

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Blood： CD19特异性CAR T细胞疗法治疗R/R B-ALL

2020-01-03

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

百时美施贵宝宣布向FDA申请其CAR-T细胞疗法liso-cel的许可

2019-12-21

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿

2019-12-19

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

CAR-T细胞疗法在美国血液学会ASH上大放异彩

2019-12-18

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Kite向FDA提交第二种CAR-T细胞疗法的申请，以治疗套细胞淋巴瘤

2019-12-18

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果

2019-12-09

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Autolus的快速解离型CAR-T细胞疗法治疗急性淋巴细胞白血病，获FDA孤儿药物指定

2019-11-08

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

科济生物CAR-T细胞疗法治疗复发或难治性多发性骨髓瘤，被FDA授予再生医学先进疗法称号

2019-11-05

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Blood：Epo刺激T细胞可增强过继性T细胞疗法的抗肿瘤活性

2019-11-03

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Blood：CD19特异性CAR T细胞疗法治疗R/R B-ALL

2019-10-23

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Blood：γ分泌酶抑制剂可增强BCMA靶向CAR T细胞疗法的功效

2019-10-03

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Sci tranal med：BAFF-R靶向CAR T细胞疗法可克服B细胞恶性肿瘤的CD19抗原缺失

2019-10-03

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Precision宣布FDA批准其靶向CD20的同种异体CAR-T细胞疗法PBCAR20A的研究新药申请IND

2019-09-19

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

CARsgen Therapeutics公司的多发性骨髓瘤CAR-T细胞疗法喜获FDA的孤儿药物指定

2019-09-05

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

2019 AACR：MultiTAA T细胞疗法治疗胰腺癌

2019-07-24

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

完全个体化肿瘤免疫疗法：一种针对个体化抗原的自体基因编辑的TCR T细胞疗法（NeoTCR-P1）

2019-07-23

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

huMNC2-CAR44 T细胞疗法治疗转移性乳腺癌

2019-06-27

科室
- - 订阅+
  - 更多科室
工具
服务